Docetaxel in gastric cancer

Drugs

Volumn 67, Issue 13, 2007, Pages 1893-1901

  Deeks, Emma D ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOSPORIN; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; KETOCONAZOLE; MITOMYCIN; OBP 401; PROTEIN BAX; PROTEIN BCL X; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTRECTOMY; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LETHARGY; LEUKOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FLUOROURACIL; HUMANS; STOMACH NEOPLASMS; TAXOIDS;

EID: 34548328291     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767130-00007     Document Type: Review

References (38)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr 30; 55 (2): 74-108
2. Van Cutsem E. Docetaxel in gastric cancer. Eur J Cancer Suppl 2004; 2 (7): 52-8
3. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003; 14 Suppl. 2: ii41-4
4. Cervantes A, Georgoulias V, Falcone A. State of the art treatment for gastric cancer: future directions. Eur J Cancer Suppl 2004; 2 (7): 40-7
5. Toffoli G, Cecchin E. Pharmacogenomics and stomach cancer. Pharmacogenomics 2004; 5 (6): 627-41
6. Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005; 10 Suppl. 3: 49-58
7. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15 (11): 1585-95
8. Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004; 9 Suppl. 2: 9-15
9. Fulton B, Spencer CM. Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51 (6): 1075-92
10. Figgit DP, Wiseman LR. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000 Mar; 59 (3): 621-51
11. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005; 65 (17): 2513-31
12. Comer AM, Goa KL. Docetaxel: a review of its use in non-small cell lung cancer. Drugs Aging 2000 Jul; 17 (1): 53-80
13. Bekaii-Saab TS, Villalona-Calero MA. Preclinical experience with docetaxel in gastrointestinal cancers. Semin Oncol 2005 Apr; 32 (2 Suppl. 4): S3-9
14. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13 (10): 2643-55
15. Kim R, Ohi Y, Inoue H, et al. Activation and the interaction of proaptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells. Int J Oncol 1999 Oct; 15 (4): 751-6
16. Kim R, Ohi Y, Inoue H, et al. Taxotere activates transcription factor AP-1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res 1999; 19: 5399-405
17. Tanaka M, Obata T, Sasaki T. Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996 Feb; 32 (2): 226-30
18. Ricotti L, Tesei A, De Paola F, et al. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines. Clin Cancer Res 2003 Feb; 9 (2): 900-5
19. Gu B, Wu D, Li M, et al. Potentiation of docetaxel antitumour activity by batimastat against mouse forestomach carcinoma. J Environ Pathol Toxicol Oncol 2000; 19 (4): 375-82
20. Maeda S, Sugiura T, Saikawa Y, et al. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci 2004 Aug; 95 (8): 679-84
21. Wada Y, Yoshida K, Suzuki T, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 2006 Aug 15; 119 (4): 783-91
22. Fujiwara T, Kagawa S, Kishimoto H, et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006 Jul 15; 119: 432-40
23. Kodera Y, Fujiwara M, Yokoyama H, et al. Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 2005 Sep-Oct 31; 19 (5): 861-6
24. Sanofi-Aventis. Taxotere summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/taxotere/ taxotere.htm [Accessed 2006 Dec 13]
25. Bissery MC, Guénard D, Guéritte-Voegelein F, et al. Experimental antitumour activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51 (18): 4845-52
26. Maeda S, Saikawa Y, Kubota T, et al. No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res 2003 Jul-Aug 31; 23 (4): 3147-50
27. Eisenhauer EA, Vermorken JB. The taxoids: comparative clinical pharmacology and therapeutic potential. Drugs 1998 Jan; 55 (1): 5-30
28. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999 Feb; 36 (2): 99-114
29. Sanofi-Aventis. Taxotere® (docetaxel) prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/20- 449s029_Taxotere_prntlbl.PDF [Accessed 2006 Dec 13]
30. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005 Aug 20; 23 (24): 5660-7
31. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007 Aug 1; 25 (22): 3217-23
32. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006 Nov 1; 24 (31): 4991-7
33. Roth AD, Maibach R, Fazio N, et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®): cisplatin in advanced gastric carcinoma: a phase I-II trial. Ann Oncol 2004 May; 15 (5): 759-64
34. Park SR, Chun JH, Kim YW, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 2005 Oct; 28 (5): 433-8
35. Oh DY, Kim TY, Kwon JH, et al. Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer. Jpn J Clin Oncol 2005 Jul; 35 (7): 380-5
36. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 2007 Aug 1; 25 (22): 3210-6
37. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007 Aug 1; 25 (22): 3205-9
38. Van Cutsem E. Novel cytotoxic regimens in gastric cancer. Eur J Cancer Suppl 2006; 4 (10): 14-8